Lizelotte T. Parren-Weppner
Almelo, OV, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.
Journal: Acta dermato-venereologica
Published: December 19, 2024
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.
Journal: Journal of psoriasis and psoriatic arthritis
Published: December 13, 2024
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Journal: American journal of clinical dermatology
Published: April 28, 2024
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Journal: Acta dermato-venereologica
Published: March 31, 2022
Germline intergenic duplications at Xq26.1 underlie Bazex-Dupré-Christol basal cell carcinoma susceptibility syndrome.
Journal: The British journal of dermatology
Published: March 01, 2022
Cutaneous presentation of a bladder carcinoma mimicking an epidermal cyst.
Journal: International journal of dermatology
Published: October 14, 2020
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Journal: The British journal of dermatology
Published: July 15, 2016
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Journal: The British journal of dermatology
Published: February 19, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026